AbCellera Q3 net loss $21.4M ($0.08/share); revenue falls to $5.5M from $9.4M

AbCellera Biologics Inc.

2021-Q3 EPS reported $0.29 revenue$235,872,000

Total revenue $5.5M, down 41% from $9.4M in Q3 2020 due to lower milestone payments and bamlanivimab royalty pause.
Net loss $21.4M ($0.08 loss per share) vs net loss $2.7M ($0.02 loss) in Q3 2020.
Cumulative program starts 69, up 35% YoY; partners increased to 35; 5 molecules in the clinic.
Acquired TetraGenetics to expand capabilities for high-value transmembrane protein targets.
Post-quarter: Eli Lilly ordered 614K additional doses of bamlanivimab with etesevimab; shipments resumed.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.